Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

ebo-controlled trial. Morphotek expects to enroll up to 900 subjects in this clinical study that will be conducted globally at sites in North America, South America, Europe, Australia and Asia.

"Ovarian cancer is a disease that is devastating to the lives of patients and caregivers," said Nicholas Nicolaides, Ph.D., President and Chief Executive Officer at Morphotek. "The agreement reached in the SPA process for farletuzumab's Phase III trial may bring us one step closer to providing hope in their lives and further exemplifies our human health care (hhc) mission to bring treatments to the people who need them most."

Farletuzumab is a monoclonal antibody that binds to and blocks the function of folate receptor alpha (FRA), a cell surface protein on tumor cells that confers a growth advantage to tumorigenic cells in vitro. FRA has been demonstrated by several independent studies to be expressed on ovarian cancer cells. Preclinical data support the theory that farletuzumab achieves its pharmacological effect by two mechanisms: first, by the capacity of farletuzumab to block signaling inside cancer cells and, second, by stimulating the patient's immune system to attack and destroy the FRA positive-tumor cells. The pre-cursor to farletuzumab was originally developed by Dr. Lloyd Old at the Ludwig Institute for Cancer Research applying his pioneering work that employed whole cell immunization of tumors to identify cell surface factors. These efforts led to the development of a panel of novel antibodies that can recognize tumor cell surface antigens as well as tumor stromal cell surface antigens. Morphotek licensed the antibody and improved it using the company's proprietary morphogenics technology.

Ovarian cancer, which ranks fifth as the cause of cancer deaths in women, usually grows asymptomatically before it is discovered. The National Cancer Institute estimates that there were 21,650 new cases of ovarian
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 2015 On June 22, 2015, Medicare ... drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... as 19 million of the 49 million Medicare beneficiaries in ... life-threatening adverse drug events.(1) Sadly, if it became a standard ... Medicine, the use of an individual’s genetic information to tailor ...
(Date:6/3/2015)... 03, 2015 Dr. Steven Reisman, a nationally ... Center ( http://www.newyorkcardiac.com ) located in NYC, announced today the ... his practice. In most cases, depending on the level of ... they call, they will be seen by a cardiologist that ... a cardiologist is to ensure that people who have an ...
(Date:6/3/2015)... Alberto Grignolo, PhD, will be honored with a ... Global Inspire Award program recognizes the organization’s outstanding volunteers ... service on a global scale. , Grignolo ... one DIA member for meritorious service through a leadership ... foster innovation to improve health and well-being worldwide. , ...
(Date:6/3/2015)... Justina Molzon, MS Pharm, JD will be honored ... Meeting. DIA’s Global Inspire Award program recognizes the organization’s ... commitment to service on a global scale. ... that recognizes the “Member of the Year” who consistently ... has contributed to the advancement of DIA’s mission. ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Visual ... Analytics solutions, today announced the launch of the ... (DSX) for SAP® BusinessObjects™ Design Studio. The Design ... visualization capabilities and advanced functionalities into their dashboarding ... DSX suite, Visual BI is adding key components ...
Breaking Medicine News(10 mins):Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3
... News) -- The pain of knee osteoarthritis is more severe ... pain, a new study has found. In the study, ... to 79, about pain in the lower back, neck, shoulder, ... back pain was significantly associated with higher knee pain scores. ...
... study released today estimates that the global initiative to ... US$40-50 billion if transmission of wild polioviruses is interrupted ... first rigorous evaluation of the benefits and costs of ... ever undertaken by the global health community. The study ...
... Oliver Daumke of the Max Delbrck Center for Molecular ... Excellence in Science Award 2010" in the biology category. ... his contributions to the understanding of the structure and ... Together with him, two other scientists, Professor Nicolai Cramer ...
... Nov. 20 (HealthDay News) -- Kidney failure patients who ... had significantly better heart function, overall health and general ... stems from an analysis that compared the impact of ... per week, for three to four hours per session ...
... News) -- If teens, desires for health care privacy ... study suggests. Teens are cautious about revealing sensitive ... judged, and are reluctant to talk to unfamiliar or ... Hospital Medical Center. The researchers conducted 12 focus ...
... financial crisis still hanging over many countries, this year,s ... Systems Financing: The Path to Universal Coverage" is timely ... that all people have access to health care services, ... a Perspective article on the 2010 World Health Report ...
Cached Medicine News:Health News:Economic benefits of the global polio eradication initiative estimated at $40-50 billion 2Health News:Doubling Frequency of Dialysis May Help Kidney Failure Patients 2Health News:Doubling Frequency of Dialysis May Help Kidney Failure Patients 3Health News:For Teens, Privacy May Trump Health Care 2
(Date:6/3/2015)...  VA North Texas Health Care System announces ... a technology-based, scientifically advanced weight loss therapy.  ... the Maestro® Rechargeable System that intermittently blocks intra-abdominal ... food intake and processing between the brain and ... to meet the needs of a patient,s changing ...
(Date:6/3/2015)... , June 3, 2015 ... a biotechnology company focused on discovering and ... of dermatology and ophthalmology, today announced that it ... United States Patent and Trademark Office (USPTO) ... The patent, titled "RNA Interference in Ocular ...
(Date:6/3/2015)... BOSTON , June 3, 2015 PillPack, ... has completed a $50 million round of financing led ... Menlo Ventures, and Sherpa Ventures. The capital will be ... world-class team, and build retail pharmacies in US markets. ... and launched a better, simpler pharmacy experience that folks ...
Breaking Medicine Technology:VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 4PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3
... University Hospitals (UH) in Cleveland, OH, and ... venture to construct a comprehensive inpatient rehabilitation hospital ... completion in October 2012, the state-of-the-art facility will ... with specialized rehabilitation nursing and a wide range ...
... Echo Therapeutics, Inc. (Nasdaq: ECTE ), ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today announced results for the period ended June 30, ... through Echo,s website at www.echotx.com . ...
Cached Medicine Technology:University Hospitals and Centerre Healthcare Announce Joint Venture to Open Comprehensive Inpatient Rehabilitation Hospital 2Echo Therapeutics Announces Second Quarter 2011 Financial Results 2Echo Therapeutics Announces Second Quarter 2011 Financial Results 3Echo Therapeutics Announces Second Quarter 2011 Financial Results 4Echo Therapeutics Announces Second Quarter 2011 Financial Results 5Echo Therapeutics Announces Second Quarter 2011 Financial Results 6
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: